Neumora Therapeutics, Inc. Common Stock (NMRA) Financials

NMRA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 153.9 million 83.2 million
Dec. 31, 2025 191.0 million 87.2 million
Sept. 30, 2025 177.8 million 45.7 million
June 30, 2025 223.8 million 40.9 million

NMRA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -46.4 million 7.4 million
Dec. 31, 2025 -47.9 million 7.4 million
Sept. 30, 2025 -46.6 million 6.0 million
June 30, 2025 -52.4 million 7.2 million

NMRA Net Income

No data available :(

NMRA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 147.1 million 119000 -
Dec. 31, 2025 182.5 million 193000 477000
Sept. 30, 2025 171.5 million 267000 523000
June 30, 2025 217.6 million 19.5 million 510000

NMRA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 179.9 million
Dec. 31, 2025 163.4 million
Sept. 30, 2025 161.8 million
June 30, 2025 161.7 million

NMRA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 38.6 million 14.3 million -
Dec. 31, 2025 16000 44.7 million 13.8 million -
Sept. 30, 2025 16000 40.5 million 12.2 million -
June 30, 2025 - 38.7 million 15.3 million -

NMRA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 8000
Dec. 31, 2025 - -
Sept. 30, 2025 - 5.0 million
June 30, 2025 - -

NMRA

Price: $1.56

52 week price:
0.72
3.65

Earnings Per Share: -1.33 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 302.0 million

Links: